PAREXEL International Corporation (PRXL)

Parexel International Corporation operates as a biopharmaceutical outsourcing company that provides clinical research and logistics, medical communications, consulting, and technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company offers clinical development, including translational medicine, early phase, phase II-III, phase IIIb/IV, biostatistics, clinical data management, clinical supply chain management, decentralized clinical trials, medical monitoring and consulting, medical writing, patient sensors, pharmacovigilance, and risk-based quality management (RBQM); outsourcing services, including functional services provider (FSP), strategic partnerships, and meeting management and logistics; consulting, including regulatory affairs consulting, clinical development strategy and planning, GxP compliance consulting, regulatory outsourcing, clinical trial regulatory services, market access and HEOR consulting, and commercial strategy (health advances); medical affairs, including the medical affairs company (TMAC), medical communications, and expanded access services; real-world evidence and late phase, including epidemiology, observational studies, and real-world data sciences; industry solutions, including pharma solutions and medical devices; and development phase solutions. Parexel International Corporation has strategic agreements with Microsoft Corporation, Synairgen plc, and CTC North GmbH & Co. KG. The company was incorporated in 1983 and is based in Newton, Massachusetts, with branches in Waltham and Billerica, Massachusetts, and Uxbridge, United Kingdom. It has additional locations throughout the world.